Irisin levels in LMNA-associated partial lipodystrophies

Diabetes & Metabolism
F BensmaïneM-C Vantyghem

Abstract

The adipo-myokine irisin regulates energy expenditure and fat metabolism. LMNA-associated familial partial lipodystrophy (FPLD2) comprises insulin resistance, muscle hypertrophy and lipoatrophy. The aim of this study was to investigate whether irisin could be a biomarker of FPLD2. This case control study included 19 FPLD2 subjects, 13 obese non-diabetic (OND) patients and 19 healthy controls (HC) of normal weight (median BMI: 26, 39 and 22 kg/m2, respectively). Serum irisin and leptin levels, body composition (DXA/MRI) and metabolic/inflammatory parameters were compared in these three groups. BMI and MRI intra-abdominal fat significantly differed among these three groups, whereas DXA total fat mass and leptin levels were higher in the OND group, but did not differ between HC and FPLD2. Lipodystrophy patients had higher intra-abdominal/total abdominal fat ratios than the other two groups. Irisin levels were higher in FPLD2 and OND patients than in HC (medians: 944, 934 and 804 ng/mL, respectively). However, irisin/leptin ratios and lean body mass percentages were strikingly higher, and lean mass indices lower, in FPLD2 and HC than in the OND (median irisin/leptin ratios: 137, 166 and 21, respectively). In the entire study group,...Continue Reading

References

May 8, 2002·The Journal of Clinical Endocrinology and Metabolism·Wasim A HaqueAbhimanyu Garg
Nov 9, 2004·The Journal of Clinical Endocrinology and Metabolism·M C VantyghemC Vigouroux
Jan 18, 2006·Human Molecular Genetics·Revekka L BoguslavskyHoward J Worman
Aug 23, 2007·The Journal of Clinical Endocrinology and Metabolism·Aurélie DecaudainCorinne Vigouroux
Aug 23, 2008·Nature·Patrick SealeBruce M Spiegelman
Jul 5, 2011·Human Molecular Genetics·Anne DutourPierre-Emmanuel Morange
Aug 26, 2011·The Journal of Clinical Endocrinology and Metabolism·Abhimanyu Garg
Sep 29, 2011·The American Journal of Pathology·Véronique BéréziatUNKNOWN Lipodystrophy Study Group
Jul 4, 2012·Annales d'endocrinologie·Marie-Christine VantyghemJean-Louis Wémeau
Jan 31, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Tizhong ShanShihuan Kuang
Feb 21, 2013·Diabetes Care·Leah R StricklandW Timothy Garvey
Feb 26, 2013·The Journal of Clinical Endocrinology and Metabolism·José María Moreno-NavarreteJosé Manuel Fernández-Real
Apr 18, 2013·PloS One·Arturo Roca-RivadaMaría Pardo
May 11, 2013·Journal of Diabetes and Its Complications·Kurt Højlund, Pontus Boström
Jun 21, 2013·The Journal of Clinical Endocrinology and Metabolism·Hongzhao JiAbhimanyu Garg
Jan 1, 2014·American Journal of Human Biology : the Official Journal of the Human Biology Council·Ana B CrujeirasFelipe F Casanueva
Mar 13, 2014·International Journal of Obesity : Journal of the International Association for the Study of Obesity·J Y HuhC S Mantzoros
Mar 10, 2015·Scientific Reports·Elke AlbrechtSteffen Maak
Aug 19, 2015·Cell Metabolism·Mark P JedrychowskiBruce M Spiegelman
Sep 25, 2015·Journal of Physiology and Biochemistry·Roger A VaughanCarole A Conn
Apr 5, 2016·Acta Physiologica·A RodríguezG Frühbeck
May 21, 2016·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A GavrieliC S Mantzoros
Jul 21, 2016·American Journal of Physiology. Endocrinology and Metabolism·Yuan ZhangLi-Jun Yang
Oct 7, 2016·The Journal of Clinical Endocrinology and Metabolism·Rebecca J BrownTohru Yorifuji

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.